# EDGAR Filing Document

**Accession Number:** 0001734005
**File Stem:** 0001213900-26-024709
**Filing Date:** 2026-3
**Character Count:** 3891
**Document Hash:** 4164e33e702be497a0b5bdd656c4536a
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-26-024709.hdr.sgml**: 20260306

**ACCESSION NUMBER**: 0001213900-26-024709

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20260306

**FILED AS OF DATE**: 20260306

**DATE AS OF CHANGE**: 20260306

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Aptorum Group Ltd
- **CENTRAL INDEX KEY:** 0001734005
- **STANDARD INDUSTRIAL CLASSIFICATION:** MEASURING & CONTROLLING DEVICES, NEC [3829]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 000000000
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38764
- **FILM NUMBER:** 26731510

**BUSINESS ADDRESS:**
- **STREET 1:** 17 HANOVER SQUARE
- **CITY:** LONDON
- **STATE:** X0
- **ZIP:** W1S 1BN
- **BUSINESS PHONE:** 852 3953 7700

**MAIL ADDRESS:**
- **STREET 1:** 17 HANOVER SQUARE
- **CITY:** LONDON
- **STATE:** X0
- **ZIP:** W1S 1BN

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549** 

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER**

**PURSUANT TO RULE 13a-16 OR 15d-16**

**UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**For the month of March 2026**

Commission File Number: **001-38764**

**APTORUM GROUP LIMITED**

**17 Hanover Square**

**London W1S 1BN, United Kingdom**

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

**EXHIBIT INDEX**

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 99.1 | [Press Release – Aptorum Group Limited Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency](ea028036401ex99-1.htm) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
|  | **Aptorum Group Limited** | **Aptorum Group Limited** | **Aptorum Group Limited** |
| Date: March 6, 2026 | By: | /s/ Ian Huen | /s/ Ian Huen |
|  |  | Name: | Ian Huen |
|  |  | Title: | CEO |

---

## Exhibit 99.1

**Exhibit 99.1**

**Aptorum Group Limited Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency**

Hong Kong, March 6, 2026 – Aptorum Group Limited (NASDAQ: APM), a leading Biotechnology company, today announced that it has received a notification from the Nasdaq Stock Market LLC dated March 5, 2026 regarding non-compliance with the minimum bid price requirement of $1 per share, as per Nasdaq Listing Rule 5550(a)(2).

The notification does not immediately affect the listing or trading of the company's shares on Nasdaq. Aptorum Group Limited has been granted a 180-calendar-day grace period, until September 1, 2026, to regain compliance with the noted listing requirement.

During this period, Aptorum Group Limited intends to evaluate all available options to restore compliance, including, if necessary, a reverse stock split. The company is committed to maintaining its Nasdaq listing and will take all reasonable measures to achieve compliance within the stipulated time frame.

About Aptorum Group Limited

Aptorum Group Limited is a pharmaceutical company, which engages in the discovery, development, and commercializing of therapeutic assets to treat diseases with unmet medical needs.

Forward-Looking Statements

This press release contains forward-looking statements that involve risks and uncertainties. These statements reflect the company's current expectations and projections about future events and are based on assumptions. Actual results may differ materially from those projected.

For further information, please contact: investor.relations@aptorumgroup.com